Polio Set To get The Nanopatch Treatment from Vaxxas

Vaxxas announces a WHO funded project to evaluate the delivery of polio vaccine using Nanopatch Australian company Vaxxas last week announced the initiation of a research project designed to evaluate the commercialisation prospects of Nanopatch, their microneedle platform for the delivery of polio vaccine. Vaxxas’ Nanopatch consists of a 1cm2 square of silicon with around 20,000 microprojections on its surface. Penetrating …

Vaxxas Selected as World Economic Forum Technology Pioneer 2015

Award Recognizes Significant Potential of Vaxxas’ Nanopatch Vaccines and Immunotherapies August 26th, 2014 Vaxxas, a biotechnology company commercializing a novel vaccine delivery platform, has been named a 2015 Technology Pioneer by the World Economic Forum. Vaxxas is one of 24 emerging technology companies from around the world and across all industries recognized for their potential to transform the future of business and …

#wvcusa Winner of the Best Venture Capital Investment: Vaxxas and One Ventures, Healthcare Ventures and Brandon Capital Partners @ViE Awards

  The Best Venture Capital Investment category was open to biotech's and those investees from an international array of private equity, VCs and investment arms. The criteria used to judge this category will be as follows: •    Outline the structure of the deal, parties involved, what it covers and the responsibilities on both sides •    Size of investees target market(s) …